Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
August 17 2022 - 4:30PM
Business Wire
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its
previously announced registered direct offering with a single
healthcare-focused U.S. institutional investor for the purchase of
48,000,000 shares of the Company’s common stock (or common stock
equivalents in lieu thereof) and warrants to purchase up to
48,000,000 shares of common stock at a combined purchase price of
$0.25, resulting in gross proceeds of approximately $12 million
before deducting placement agent fees and other offering expenses.
The warrants have an exercise price of $0.2554 per share and are
exercisable for a five-year period after the six-month anniversary
of the date of issuance.
The Company intends to use the net proceeds from the offering
for general corporate purposes.
A.G.P./Alliance Global Partners acted as sole placement agent
for the offering.
This offering of the common stock, common stock equivalents and
warrants is being made pursuant to an effective shelf registration
statement on Form S-3 (File No. 333-235945) previously filed with
the U.S. Securities and Exchange Commission (the “SEC”). A final
prospectus supplement describing the terms of the proposed offering
has been filed with the SEC and is available on the SEC’s website
located at http://www.sec.gov. Electronic copies of the prospectus
supplement may be obtained, when available, from A.G.P./Alliance
Global Partners, 590 Madison Avenue, 28th Floor, New York, NY
10022, or by telephone at (212) 624-2060, or by email at
prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
"off-the-shelf" stem cell product, initially for disease
indications in the neurological, inflammatory and immune and other
critical care indications and has two ongoing clinical trials
evaluating this potential regenerative medicine product. Investors
and others should note that we may post information about the
Company on our website at www.athersys.com and/or on our accounts
on Twitter, Facebook, LinkedIn or other social media platforms. It
is possible that the postings could include information deemed to
be material information. Therefore, we encourage investors, the
media and others interested in the Company to review the
information we post on our website at www.athersys.com and on our
social media accounts. Follow Athersys on Twitter at
www.twitter.com/athersys. Information that we may post about the
Company on our website and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. You should not place undue reliance on
forward-looking statements contained on our website and/or on our
accounts on Twitter, Facebook, LinkedIn or other social media
platforms, and we undertake no obligation to publicly update
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220817005065/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024